Clinical Trial Update: Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of pembrolizumab and eribulin in patients with HR+/HER2- metastatic breast cancer previously treated with anthracyclin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: MedSIR | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-02-19